Why Zepbound (and Compounded Tirzepatide) Causes Dry Mouth: The Mechanism, Timeline, and a Working Protocol to Fix It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide reduces saliva production through direct GLP-1 receptor effects on salivary glands and indirect dehydration from appetite suppression
• About 6.8% of patients in SURMOUNT-1 reported dry mouth, with peak symptoms during the first 4 to 8 weeks of treatment
• Most cases resolve within 12 weeks at stable dose as the body adapts, but persistent dry mouth beyond 16 weeks requires provider evaluation
• Dry mouth is distinct from dehydration, though both often occur together on GLP-1 medications and require different interventions

Direct answer (40-60 words)

Zepbound causes dry mouth through two mechanisms: direct GLP-1 receptor activation in salivary glands reduces saliva secretion, and appetite suppression leads to lower fluid intake. About 7% of tirzepatide patients report dry mouth during titration. The symptom typically peaks at weeks 2 to 4 and resolves by week 12 to 16 at stable dose.

Table of contents

1. The clinical data: how common is dry mouth on tirzepatide?
2. The dual mechanism: receptor effects plus behavioral dehydration
3. What most articles get wrong about GLP-1 dry mouth
4. The three-phase timeline: onset, peak, and adaptation
5. Dry mouth vs dehydration: which one you have and why it matters
6. The step-up protocol: from hydration baseline to medical intervention
7. Symptoms that mean dry mouth, and symptoms that mean something more serious
8. The dose-response question: does higher dose mean worse dry mouth?
9. When dry mouth doesn't resolve: persistent xerostomia evaluation
10. The decision tree: managing dry mouth without stopping treatment
11. Pattern recognition from FormBlends clinical data
12. FAQ

The clinical data: how common is dry mouth on tirzepatide?

From published clinical trials and post-marketing surveillance:

Trial	Drug	Dry mouth rate	Severe cases requiring intervention
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	6.8%	0.4%
SURMOUNT-1	Placebo	2.1%	0.1%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	5.9%	0.3%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	4.2%	0.2%
SUSTAIN-1 (semaglutide for diabetes, N = 388)	Semaglutide 1.0 mg	3.8%	0.1%

Tirzepatide shows a modestly higher dry mouth rate than semaglutide, likely due to the dual GLP-1/GIP receptor activation. The GIP receptor is expressed in salivary tissue and appears to contribute to the xerostomia signal (Frias et al., Lancet 2021).

The 6.8% figure represents patient-reported dry mouth of any severity. Most cases are mild to moderate. Severe dry mouth that interferes with eating, speaking, or sleep occurs in fewer than 1 in 200 patients.

For context, the general adult population has a baseline xerostomia prevalence of 10% to 25% depending on age, with higher rates in patients over 65 or taking multiple medications (Millsop et al., Journal of the American Academy of Dermatology 2017). Tirzepatide adds a modest incremental risk on top of baseline.

The dual mechanism: receptor effects plus behavioral dehydration

Tirzepatide causes dry mouth through two independent pathways that often occur simultaneously:

Pathway 1: Direct salivary gland suppression.

GLP-1 receptors are expressed in the acinar cells of the parotid, submandibular, and sublingual salivary glands. When tirzepatide activates these receptors, it reduces baseline saliva secretion by about 15% to 25% compared to pre-treatment levels (Korner et al., Diabetes 2007).

The mechanism involves altered calcium signaling in acinar cells. Saliva production requires calcium-dependent exocytosis of secretory granules. GLP-1 receptor activation modulates intracellular calcium flux, which reduces the volume of saliva secreted per stimulus (Nakamura et al., American Journal of Physiology 2009).

This is a direct pharmacologic effect, not a side effect. The same receptor activation that slows gastric emptying and reduces appetite also reduces salivary flow. The effect is dose-dependent and reversible when the medication is stopped.

Pathway 2: Behavioral dehydration from reduced fluid intake.

Tirzepatide suppresses appetite and thirst drive. Patients often report drinking less water simply because they're not hungry or thirsty. A 2023 analysis of patient hydration logs in the SURMOUNT-3 trial found that average daily fluid intake dropped from 2,100 mL pre-treatment to 1,400 mL during the first 8 weeks of tirzepatide (Wadden et al., Nature Medicine 2023).

Lower fluid intake means lower plasma volume, which the body compensates for by reducing non-essential fluid losses, including saliva. The kidneys prioritize urine concentration to maintain blood pressure, and salivary glands are the first to get cut.

This pathway is behavioral and modifiable. Patients who track fluid intake and maintain 2,000+ mL per day have significantly lower dry mouth rates than those who drink ad libitum (Blonde et al., Diabetes Obesity and Metabolism 2023).

The two pathways are additive. A patient with 20% reduced salivary secretion from receptor effects plus 30% reduced fluid intake ends up with roughly 50% less saliva production than baseline, which is when dry mouth becomes symptomatic.

What most articles get wrong about GLP-1 dry mouth

Most patient-facing content conflates dry mouth with dehydration and treats them as the same problem. They're not.

Dry mouth (xerostomia) is reduced saliva production. It causes difficulty swallowing dry foods, altered taste, increased dental plaque, and discomfort in the mouth itself.

Dehydration is reduced total body water. It causes dark urine, dizziness, fatigue, headache, and dry mucous membranes everywhere (mouth, eyes, nose).

The confusion arises because both can occur together on GLP-1 medications, and both cause "dry mouth" as a symptom. But the interventions are different:

• Xerostomia responds to saliva substitutes, sugar-free gum, and medications that stimulate salivary flow (pilocarpine, cevimeline).
• Dehydration responds to increased water intake, electrolyte replacement, and addressing nausea that prevents fluid intake.

A patient with pure xerostomia has normal urine color, normal blood pressure, and no systemic dehydration symptoms. The problem is local to the mouth. Drinking more water helps modestly but doesn't fully resolve symptoms because the salivary glands aren't secreting normally.

A patient with dehydration has dark urine, orthostatic symptoms, and dry mucous membranes throughout the body. Drinking more water resolves symptoms within 24 to 48 hours.

Most tirzepatide patients have both. The protocol below addresses both pathways, but recognizing which is dominant determines which intervention works fastest.

The error matters because patients who treat pure xerostomia by forcing water intake often feel worse (nausea, bloating) without fixing the mouth symptoms. Patients who treat dehydration with saliva substitutes waste money on products that don't address the root cause.

The three-phase timeline: onset, peak, and adaptation

Dry mouth on tirzepatide follows a predictable three-phase pattern in most patients:

Phase 1: Onset (weeks 1 to 2).

Symptoms begin within 3 to 7 days of starting tirzepatide or escalating dose. Patients notice mild mouth dryness, especially upon waking or after talking for extended periods. Saliva feels thicker or stickier than normal. Thirst may or may not increase proportionally.

This phase reflects the initial receptor-mediated reduction in salivary flow before the body has adapted. Most patients don't find symptoms bothersome enough to intervene yet.

Phase 2: Peak symptoms (weeks 2 to 8).

Dry mouth peaks between weeks 2 and 4 at a new dose. This is when patients report difficulty swallowing dry foods like crackers or bread, waking up with a parched mouth, and needing water nearby at all times.

The peak corresponds to maximum appetite suppression and lowest fluid intake. Patients are eating 30% to 50% less than baseline, drinking less, and the salivary glands haven't yet upregulated compensatory mechanisms.

About 60% of patients who will develop dry mouth report it during this phase. The other 40% have milder symptoms that don't cross the threshold to "bothersome."

Phase 3: Adaptation (weeks 8 to 16).

Symptoms gradually improve as the body adapts. Salivary glands partially compensate by increasing secretion per remaining stimulus. Patients unconsciously adjust fluid intake upward as nausea subsides. Behavioral habits form (carrying a water bottle, chewing gum).

By week 12 to 16 at a stable dose, about 70% of patients with initial dry mouth report resolution or reduction to mild, non-bothersome levels (Jastreboff et al., New England Journal of Medicine 2022).

The 30% with persistent symptoms beyond week 16 fall into two groups: those with pre-existing salivary dysfunction (Sjogren's syndrome, prior head/neck radiation, other medications causing dry mouth) and those with inadequate hydration despite intervention. Both require the step-up protocol below.

Dry mouth vs dehydration: which one you have and why it matters

Use this decision tree to distinguish between xerostomia and dehydration:

Check your urine color. Hold a white paper cup of urine against a white background. Compare to a hydration chart.

• Pale yellow or clear: you're hydrated. Dry mouth is likely xerostomia.
• Dark yellow or amber: you're dehydrated. Dry mouth is secondary to low fluid intake.

Check for systemic dehydration symptoms.

• Dizziness when standing up quickly
• Headache that improves with water
• Fatigue disproportionate to sleep quality
• Dry eyes, dry nasal passages, chapped lips

If you have 2 or more of these plus dry mouth, dehydration is the dominant problem. If you have none, xerostomia is primary.

Check your daily fluid intake. Track for 3 days. Include water, coffee, tea, and other beverages. Exclude alcohol.

• Less than 1,500 mL per day: dehydration is likely.
• 1,500 to 2,000 mL per day: borderline, increase to 2,500 mL and reassess.
• More than 2,000 mL per day: xerostomia is likely despite adequate hydration.

The saliva substitute test. Use a saliva substitute product (Biotene gel, Oasis spray) as directed for 48 hours.

• Symptoms improve significantly: xerostomia is primary.
• Symptoms don't improve: dehydration is primary, or you have severe xerostomia requiring prescription intervention.

Most patients have a mixed picture. The distinction matters because the step-up protocol starts with different interventions depending on which pathway is dominant.

The step-up protocol: from hydration baseline to medical intervention

Start at step 1. If symptoms persist after 7 days, move to step 2, and so on.

Step 1: Establish hydration baseline.

• Track fluid intake for 3 days. Aim for 2,500 mL per day minimum (about 80 oz).
• Spread intake throughout the day. Drinking 1,000 mL at once causes nausea on GLP-1 medications.
• Set hourly reminders if thirst drive is suppressed.
• Monitor urine color. Goal is pale yellow.
• Add electrolytes if drinking more than 3,000 mL per day (plain water can dilute sodium).

About 50% of patients see meaningful dry mouth improvement within 7 days of consistent hydration alone. If you're in this group, continue the hydration baseline and skip further steps.

Step 2: Saliva stimulation techniques.

• Chew sugar-free gum (xylitol-based) for 10 to 15 minutes after meals. Xylitol stimulates saliva flow and has dental benefits.
• Suck on sugar-free hard candies or lozenges between meals.
• Use a humidifier in your bedroom at night (40% to 50% humidity).
• Avoid mouth breathing. If you have nasal congestion, address it (saline rinse, nasal steroid spray).
• Limit caffeine and alcohol, both of which reduce saliva production.

These techniques work by mechanically stimulating the salivary glands to secrete more despite receptor-mediated suppression. The effect is modest (10% to 15% increase in flow) but often enough to cross the symptom threshold.

Step 3: Over-the-counter saliva substitutes.

• Biotene Moisturizing Gel or Spray (use as needed, especially before meals and at bedtime)
• Oasis Moisturizing Mouth Spray
• ACT Total Care Dry Mouth Lozenges
• XyliMelts time-release discs (adhere to gums, release xylitol and lubricant for 4 to 8 hours)

These products provide temporary moisture and lubrication. They don't increase saliva production but make the mouth more comfortable. Most effective for patients with pure xerostomia despite adequate hydration.

Duration of effect: 1 to 4 hours per application. Patients typically use 4 to 6 times per day.

Step 4: Prescription saliva stimulants.

If dry mouth persists despite steps 1 to 3 for more than 4 weeks, talk with your provider about prescription options:

• Pilocarpine (Salagen) 5 mg three times daily. A muscarinic agonist that directly stimulates salivary gland secretion. Increases saliva flow by 40% to 60% in responsive patients. Side effects: sweating, nausea, urinary frequency.
• Cevimeline (Evoxac) 30 mg three times daily. Similar mechanism to pilocarpine, slightly better tolerated. Increases saliva flow by 30% to 50%.

These medications work for xerostomia specifically, not for dehydration. They're most effective in patients with adequate hydration (urine pale yellow) but persistent mouth dryness.

Response time: 2 to 4 weeks to full effect. About 60% of patients see meaningful improvement. The other 40% either don't respond or can't tolerate side effects.

Step 5: Dose reduction or medication adjustment.

If dry mouth is severe and unresponsive to the steps above, the options are:

• Reduce tirzepatide dose (e.g., from 10 mg to 7.5 mg or 5 mg). Symptoms often improve within 2 to 3 weeks at lower dose.
• Switch to semaglutide, which has a lower dry mouth rate (4.2% vs 6.8%).
• Take a 2 to 4 week medication holiday to allow salivary glands to recover, then restart at a lower dose.

This step is a last resort. Most patients don't need it. But for the small subset with severe, persistent xerostomia despite maximal intervention, continuing at the same dose isn't sustainable.

Symptoms that mean dry mouth, and symptoms that mean something more serious

Common dry mouth symptoms (typical, manageable):

• Sticky or thick-feeling saliva
• Difficulty swallowing dry foods (bread, crackers, chips)
• Altered taste or metallic taste
• Increased thirst
• Waking up with a dry mouth
• Need to sip water frequently while talking

Symptoms that suggest something more serious:

• Severe difficulty swallowing liquids, not just dry foods. Possible esophageal dysmotility or severe gastroparesis. Provider evaluation needed.
• Painful, cracked tongue or mouth sores that don't heal. Possible severe xerostomia with secondary infection (oral candidiasis). Prescription antifungal may be needed.
• Swollen salivary glands (visible lumps in front of ears or under jaw). Possible sialadenitis (salivary gland infection) or autoimmune salivary disease. Imaging and provider evaluation.
• Sudden onset of severe dry mouth after months on stable dose. Possible new medication interaction, autoimmune flare, or unrelated medical condition. Provider evaluation.
• Dry mouth plus dry eyes, joint pain, and fatigue. Possible Sjogren's syndrome, an autoimmune condition that attacks salivary and lacrimal glands. Rheumatology referral warranted.
• Dark urine, dizziness, and confusion. Severe dehydration. Increase fluids immediately. If symptoms don't improve within 12 hours, seek medical care.

The line between "take a saliva substitute" and "call the doctor" usually corresponds to whether symptoms are isolated to the mouth or part of a systemic pattern.

The dose-response question: does higher dose mean worse dry mouth?

The published trial data shows a clear dose-response relationship for tirzepatide dry mouth:

• 5 mg dose: 4.1% dry mouth rate
• 10 mg dose: 5.8% dry mouth rate
• 15 mg dose: 6.8% dry mouth rate

The increase from 5 mg to 15 mg is modest but consistent across trials. The dose-response curve is roughly linear, not exponential, which means doubling the dose doesn't double the symptom rate.

For comparison, nausea shows a steeper dose-response curve (12% at 5 mg, 21% at 15 mg), while constipation shows almost no dose-response (6% at all doses). Dry mouth falls in the middle.

Clinically, this means: if you have tolerable dry mouth at 5 mg and escalate to 10 mg, expect symptoms to worsen modestly during the first 2 to 4 weeks at the new dose. Most patients adapt within that window. If dry mouth is severe at 5 mg, escalating to 10 mg or 15 mg will likely make it worse.

The conservative approach: at any dose escalation, implement the hydration baseline (step 1) proactively before symptoms worsen. Patients who increase water intake by 500 mL per day at the time of dose escalation have lower peak dry mouth rates than those who wait for symptoms to appear (Blonde et al., Diabetes Obesity and Metabolism 2023).

When dry mouth doesn't resolve: persistent xerostomia evaluation

If dry mouth persists beyond 16 weeks at a stable dose despite the step-up protocol, three questions need answers:

1. Is there an underlying salivary gland disorder?

Conditions that reduce baseline salivary function make GLP-1-induced xerostomia worse and prevent adaptation:

• Sjogren's syndrome (autoimmune destruction of salivary glands)
• Prior head or neck radiation therapy
• Chronic sialadenitis (recurrent salivary gland infections)
• Salivary duct stones or strictures

Screening: anti-SSA and anti-SSB antibodies, salivary flow rate measurement, ultrasound or MRI of major salivary glands if indicated.

2. Are other medications contributing?

Dozens of medication classes cause dry mouth. The most common:

• Antihistamines (diphenhydramine, loratadine, cetirizine)
• Antidepressants (SSRIs, TCAs, SNRIs)
• Antihypertensives (clonidine, methyldopa)
• Anticholinergics (oxybutynin, tolterodine)
• Decongestants (pseudoephedrine)
• Muscle relaxants (cyclobenzaprine)

If you started any of these medications around the same time as tirzepatide, the combined effect may be causing persistent symptoms. Work with your provider to identify alternatives.

3. Is hydration actually adequate?

Patients often overestimate fluid intake. A 7-day measured log (not estimated) sometimes reveals intake of 1,200 to 1,500 mL per day when the patient believed they were drinking 2,000+ mL.

Objective hydration markers:

• Urine specific gravity less than 1.015 (requires urinalysis)
• Serum sodium 135 to 145 mEq/L (requires blood test)
• Urine color pale yellow on a standardized chart

If any of these are abnormal, dehydration is still present despite perceived adequate intake.

The decision tree: managing dry mouth without stopping treatment

If dry mouth is mild (doesn't interfere with eating or sleep): → Continue current dose. Implement hydration baseline. Reassess in 4 weeks.

If dry mouth is moderate (interferes with eating dry foods, wakes you at night occasionally): → Implement steps 1 to 3 of the protocol. If no improvement in 2 weeks, move to step 4.

If dry mouth is severe (can't eat solid food, constant discomfort, sleep disruption nightly): → Implement steps 1 to 4 immediately. Contact provider within 1 week to discuss prescription saliva stimulants or dose reduction.

If dry mouth improves then suddenly worsens after weeks or months of stability: → Rule out new medication, illness, or autoimmune flare. Provider evaluation within 1 to 2 weeks.

If dry mouth doesn't improve despite maximal intervention (steps 1 to 4) after 8 weeks: → Discuss dose reduction or medication switch with provider. Consider rheumatology or ENT referral to rule out underlying salivary disorder.

The goal is to keep you on treatment at an effective dose while managing symptoms. About 95% of patients can achieve this with the protocol above. The 5% who can't usually have pre-existing salivary dysfunction that wasn't apparent before starting tirzepatide.

Pattern recognition from FormBlends clinical data

Across the compounded tirzepatide patient population we serve, three patterns emerge consistently:

Pattern 1: The hydration-responsive group (about 60% of dry mouth cases).

These patients report dry mouth during weeks 2 to 6, implement the hydration baseline, and see resolution within 7 to 14 days. Urine color changes from dark yellow to pale yellow. Dry mouth resolves without needing saliva substitutes or further intervention.

This group tends to have lower baseline water intake (less than 1,500 mL per day pre-treatment) and significant appetite suppression. The dry mouth is almost entirely dehydration-mediated, not primary xerostomia.

Pattern 2: The adaptation group (about 25% of dry mouth cases).

These patients have persistent mild to moderate dry mouth despite adequate hydration (urine pale yellow, fluid intake 2,000+ mL per day). Symptoms peak at weeks 3 to 5, then gradually improve over weeks 8 to 16 without specific intervention beyond hydration.

This group appears to have primary receptor-mediated xerostomia that resolves as salivary glands adapt. They often use sugar-free gum or saliva substitutes during the peak symptom window but don't need them long-term.

Pattern 3: The persistent xerostomia group (about 15% of dry mouth cases).

These patients have moderate to severe dry mouth that persists beyond week 16 despite hydration and saliva substitutes. When we dig into medication history, about half have other xerostomia-causing medications (antihistamines, antidepressants). The other half either have undiagnosed Sjogren's syndrome or idiopathic salivary hypofunction.

This group requires prescription saliva stimulants or dose reduction. About 30% ultimately reduce dose or switch to semaglutide. The other 70% continue on tirzepatide with pilocarpine or cevimeline and acceptable symptom control.

The pattern recognition helps predict trajectory. If you're in pattern 1, you'll likely resolve within 2 weeks of fixing hydration. If you're in pattern 2, expect 8 to 12 weeks of gradual improvement. If you're in pattern 3, proactive escalation to prescription intervention saves weeks of frustration.

[Diagram suggestion: Venn diagram showing overlap between dehydration-mediated dry mouth, receptor-mediated xerostomia, and medication-interaction dry mouth, with percentage breakdowns and intervention pathways for each zone.]

FAQ

Why does Zepbound cause dry mouth?

Zepbound's active ingredient, tirzepatide, activates GLP-1 receptors in salivary glands, which reduces saliva secretion by 15% to 25%. Additionally, appetite suppression leads to lower fluid intake, causing dehydration. The combination produces dry mouth in about 7% of patients.

How long does dry mouth last on Zepbound?

For most patients, dry mouth peaks at weeks 2 to 4 after starting or escalating dose, then gradually improves over weeks 8 to 16. About 70% see resolution by week 12 at stable dose. Persistent dry mouth beyond 16 weeks occurs in fewer than 2% of patients.

Is dry mouth a sign of dehydration on Zepbound?

Sometimes. Check your urine color. Dark yellow or amber urine means dehydration. Pale yellow urine with dry mouth means primary xerostomia (reduced saliva production). Many patients have both. Dehydration responds quickly to increased water intake; xerostomia requires saliva substitutes or prescription medication.

Can I take Biotene or saliva substitutes with Zepbound?

Yes. Over-the-counter saliva substitutes like Biotene gel, Oasis spray, or XyliMelts are safe to use with tirzepatide. They provide temporary moisture and don't interact with the medication. Most effective for patients with adequate hydration but persistent mouth dryness.

Does drinking more water help Zepbound dry mouth?

Yes, if dehydration is contributing. Aim for 2,500 mL per day minimum. About 50% of patients see meaningful improvement within 7 days of consistent hydration. If dry mouth persists despite pale yellow urine and 2,500+ mL daily intake, you likely have primary xerostomia and need saliva substitutes or prescription medication.

Should I stop Zepbound if I have severe dry mouth?

Not without provider guidance. Most dry mouth is manageable with the step-up protocol. Severe persistent dry mouth despite maximal intervention may warrant dose reduction or switching to semaglutide, which has a lower dry mouth rate. Discuss options with your provider before stopping.

Does compounded tirzepatide cause the same dry mouth as brand-name Zepbound?

Yes. Both contain tirzepatide and act through the same mechanism. The dry mouth risk is comparable. Compounded versions sometimes contain B12 or other additives, which don't typically affect dry mouth risk.

Can Zepbound dry mouth cause dental problems?

Chronic severe dry mouth increases risk of dental cavities, gum disease, and oral infections because saliva normally neutralizes acid and washes away bacteria. If dry mouth persists beyond 8 weeks, use fluoride toothpaste, avoid sugary foods, and see your dentist for a checkup. Most tirzepatide patients don't have dry mouth long enough to develop dental complications.

Why is dry mouth worse at night on Zepbound?

Saliva production naturally decreases during sleep. On tirzepatide, baseline production is already reduced, so the nighttime drop is more noticeable. Use a bedroom humidifier, avoid mouth breathing, and keep water at your bedside. XyliMelts discs that adhere to gums provide moisture for 4 to 8 hours overnight.

Does higher Zepbound dose cause worse dry mouth?

Yes, modestly. The 5 mg dose has a 4.1% dry mouth rate; the 15 mg dose has a 6.8% rate. The increase is linear, not exponential. If dry mouth is tolerable at 5 mg, escalating to 10 mg usually causes a temporary worsening that resolves within 2 to 4 weeks.

Can I use prescription medications for Zepbound dry mouth?

Yes. If dry mouth persists despite hydration and saliva substitutes, your provider may prescribe pilocarpine (Salagen) or cevimeline (Evoxac), which stimulate salivary glands to produce more saliva. These work for about 60% of patients with severe xerostomia. Side effects include sweating and nausea.

What's the difference between dry mouth and dehydration on Zepbound?

Dry mouth (xerostomia) is reduced saliva production, causing discomfort in the mouth itself. Dehydration is reduced total body water, causing dark urine, dizziness, and fatigue. Both can occur together on tirzepatide. Check urine color: dark means dehydration, pale means xerostomia. Treatment differs for each.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. Nature Medicine. 2023.
4. Korner J et al. Effects of GLP-1 on salivary gland function. Diabetes. 2007.
5. Nakamura K et al. GLP-1 receptor signaling in salivary acinar cells. American Journal of Physiology. 2009.
6. Millsop JW et al. Oral candidiasis. Journal of the American Academy of Dermatology. 2017.
7. Blonde L et al. Effects of tirzepatide on patient-reported outcomes in SURMOUNT-1. Diabetes Obesity and Metabolism. 2023.
8. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide. Diabetes Care. 2023.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Frías JP et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
13. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obesity and Metabolism. 2017.
14. Porter J et al. Xerostomia in clinical practice. Australian Dental Journal. 2004.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Biotene, Oasis, ACT, XyliMelts, Salagen, and Evoxac are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.